Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 26181023)

  • 1. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are We Making Progress in Lung Cancer Using Progression-Free Survival as a Surrogate End Point?
    Shyr Y; Horn L; Berry L
    JAMA Oncol; 2015 May; 1(2):202-3. PubMed ID: 26181024
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
    JAMA Oncol; 2015 Dec; 1(9):1293-300. PubMed ID: 26313558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
    Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
    Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
    J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
    Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
    Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
    JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
    Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
    J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.
    Ahn MJ; Tsai CM; Hsia TC; Wright E; Chang JW; Kim HT; Kim JH; Kang JH; Kim SW; Bae EJ; Kang M; Lister J; Walzer S
    Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():22-33. PubMed ID: 21585705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and lung cancer clinical trials.
    Du W; Reeves JH; Gadgeel S; Abrams J; Peters WP
    Cancer; 2003 Oct; 98(7):1491-6. PubMed ID: 14508837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
    Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
    Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
    Kwan SW; Mortell KE; Hippe DS; Brunner MC
    J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer.
    Hashim M; Pfeiffer BM; Bartsch R; Postma M; Heeg B
    Value Health; 2018 Jan; 21(1):9-17. PubMed ID: 29304946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research.
    Grutters JP; Pijls-Johannesma M; Ruysscher DD; Peeters A; Reimoser S; Severens JL; Lambin P; Joore MA
    Cancer Treat Rev; 2010 Oct; 36(6):468-76. PubMed ID: 20303217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.